Global Malignant Mesothelioma Therapeutic Market Growth (Status and Outlook) 2023-2029

Global Malignant Mesothelioma Therapeutic Market Growth (Status and Outlook) 2023-2029

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
LPI (LP Information)' newest research report, the “Malignant Mesothelioma Therapeutic Industry Forecast” looks at past sales and reviews total world Malignant Mesothelioma Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Malignant Mesothelioma Therapeutic sales for 2023 through 2029. With Malignant Mesothelioma Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Malignant Mesothelioma Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Malignant Mesothelioma Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Malignant Mesothelioma Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Malignant Mesothelioma Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Malignant Mesothelioma Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Malignant Mesothelioma Therapeutic.
The global Malignant Mesothelioma Therapeutic market size is projected to grow from US$ 322.6 million in 2022 to US$ 527 million in 2029; it is expected to grow at a CAGR of 7.3% from 2023 to 2029.
The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report presents a comprehensive overview, market shares, and growth opportunities of Malignant Mesothelioma Therapeutic market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pemetrexed
Cisplatin
Others
Segmentation by application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.